Article
The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
International journal of laboratory hematology - 1 Oct 2008
Goulding C, Uttenthal B, Foroni L, Duke V, Traore A, Kottaridis P, Hoffbrand A V, Patch D, McNamara C
Abstract excerpt
Clinically latent myeloproliferative disorders (MPDs) are important causes of what would otherwise be considered idiopathic hepatic (HVT) or portal vein thrombosis (PVT). They may be difficult to diagnose initially because the peripheral blood count may be normal at the time of thrombosis. A strong association between an activating mutation of the gene encoding one of the Janus kinase family of tyrosine kinases...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.